SpringerLink
Log in

Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9 fractions, and in rats, dogs and humans

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

The in vitro and in vivo metabolism of the nonbenzodiazepine anxiolytic agent, RWJ-51204 was investigated after incubation with mice, rat, dog, monkey, and human hepatic S9 fractions in the presence of NADPH-generating system, and a single oral dose administration to rats (100 mg/kg), dogs (5 mg/kg), and humans (2.5 mg/subject). Plasma and red blood cells (2 h, rat) and urine samples (0–24 h, rat, dog and human) were obtained postdose. Unchanged RWJ-51204 (39–93% of the sample in vitro; ≤5% of the sample in vivo) plus 14 metabolites were profiled, quantified and tentatively identified on the basis of API-MS and MS/MS data, and by comparison of synthetic samples.

The in vitro and in vivo metabolic pathways for RWJ-51204 are proposed, and the metabolite formations are via the following five pathways: 1. phenyl oxidation, 2. pyrido-oxidation, 3. N-deethoxymethylation, 4. dehydration, and 5. glucuronidation. Pathway 1 formed 4-hydroxy-2-fluoro-phenyl-RWJ-51204 (Ml, 7–24% in vitro; 5–60% in vivo) in major amounts, OH-benzimidazole-RWJ-51204 (M2, 5–8% in vitro and in vivo) and diOH-phenyl-RWJ-51204 (≤5–16% in vitro and in vivo); in conjunction with pathway 5 produced Ml glucuronide (60% in rat & dog; 17% in human), M2 glucuronide (16% in human). Pathways 2–4 formed minor/trace oxidized, and dehydrated metabolites. RWJ-51204 is extensively metabolized in vitro (except dog) and in vivo in rats, dogs and humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Spain)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maryanoff, B.E., Ho, W., McComsey, D.F., Reitz, A.B., Grous, P.P, Nortey, S.O., Shank, R.P., Dubinsky, B., Taylor, Jr., R.J, Gardocki, J.F., (1995): Potential anxiolytic agents, pyrido[l,2-a]benzimidazole: anew structural class of ligands for the benzodiazepine binding site on GABA-A receptors, J. Med. Chem., 38,16–20.

    Article  CAS  PubMed  Google Scholar 

  2. Maryanoff, B.E., McComsey, D.F., Ho, W., Shank, R.P., and Dubinsky, B., (1996): Potential anxiolytic agents — II. Improvement of oral efficacy for the pyrido[l,2-a]benzimidazole (PBI) class of GABA-A receptor modulators, Bioorg. Med. Chem. Lett., 6, 333–338.

    Article  CAS  Google Scholar 

  3. Reitz, A.B., Jordan, A.D., Sanfilippo, P.J., and Vavouyios-Smith, A., ( 1998): US Patent, 5,817,668,6.

  4. Maryanoff, B.E., Nortey, S.O., McNally, J.J., Sanfilippo, P.J., McComsey, D.F., Dubinsky, B., Shank, R.P., and Reitz, A.B., (1999): Potential anxiolytic agents. 3. Novel A-ring modified pyrido[ 1,2-a]benzimidazole, Bioorg. Med. Chem. Lett., 9 1547–1552.

    Article  CAS  PubMed  Google Scholar 

  5. Scott, M.K., Demeter, D.A., Nortey, S.O., Dubinsky, B., Shank, R.P., and Reitz, A.B., (1999): 4 New directions in anxiolytic drug research, Prog. Med. Chem., 36,169–200.

    Article  CAS  PubMed  Google Scholar 

  6. Jordan, A.D., Vaidya, A.H., Rosenthal, D.I., Dubinsky, B., Kordik, C.P., Sanfilippo, P.J., Wu, W.N., and Reitz, A.B., (2002): Potential anxiolytic agents, part 4: novel orally-active N5-substituted pyrido[l,2-a]benzimidazoles with high GABA-A receptor affinity, Bioorg. Med. Chem. Lett.,12,2381–2386.

    Article  CAS  PubMed  Google Scholar 

  7. Dubinsky, B., Vaidya, A.H., Rosenthal, D.I., Hochman, C., Crooke, J.J., Deluca, S., Devine, A., Cheo-Isaacs, C.T., Carter, A.R., Jordan, A.D., Reitz, A.B. and Shank, R.P., (2002): 5-Ethoxymethyl-7-fluoro-3-oxo-l,2,3,5-tetrahydrobenzo[4,5]imidazo [l,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic, J. Pharmacol. Exp. Ther., 303,777–790.

    Article  CAS  PubMed  Google Scholar 

  8. Wu, W.N., McKown, L.A., Reitz, A.B., andTakacs, A.R., (1998): In vitro metabolism of the anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9. The AAPS Annual Meeting and Exposition, Abstract no. 1167, Pharm. Sei., 1, PS36.

  9. Wu, W.N., and McKown, L.A., (1999): In vivo metabolism of anxiolytic agent, RWJ-51204, in the rat and dog, The 9th N. Amer. ISSX/ACS-DCT Meeting, Abstract no. 34, ISSX Proceedings, 15,174.

  10. Wu, W.N., McKown, L.A., and Reitz, A.B., (2002): Metabolism of the anxiolytic agent, RWJ-51204, in human (2.5 mg/subject single oral dose), catalyzed by CYP3A4 isoform, The 11th N. Amer. ISSX Meeting, Abstract no. 163, Drug Metab. Rev., 34,82.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Welsh & McKean Roads, 19477, Spring House, PA, USA

    W. N. Wu, L. A. McKown & A. B. Reitz

Authors
  1. W. N. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. A. McKown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. B. Reitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, W.N., McKown, L.A. & Reitz, A.B. Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9 fractions, and in rats, dogs and humans. European Journal of Drug Metabolism and Pharmacokinetics 29, 263–268 (2004). https://doi.org/10.1007/BF03190609

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190609

Keywords

Search

Navigation